• Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

  • Jul 15 2024
  • Duración: 9 m
  • Podcast

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment  Por  arte de portada

Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

  • Resumen

  • Dawn Brooks, PhD, Global Development Leader, Eli Lilly and Company, and John Sims, MD, Senior Medical Director, Eli Lilly and Company, discuss new findings on baseline characteristics about amyloid-related imaging abnormalities (ARIA) in people with Alzheimer disease treated with donanemab.
    Más Menos
activate_primeday_promo_in_buybox_DT

Lo que los oyentes dicen sobre Strategies to Limit ARIA Associated with Alzheimer Disease Treatment

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.